



GlaxoSmithKline

March 26, 2014

**NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA 5TH FLOOR
PLOT No. C/1 G BLOCK
BANDRA-KURLA COMPLEX
BANDRA (EAST)
MUMBAI
400051**

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494


Dear Sir,

**SECURITIES & EXCHANGE BOARD OF INDIA
(Prohibition of Insider Trading) Regulations, 1992**

Pursuant to the Regulation 13(3) & 13(6) of the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, we enclose herewith an intimation dated 24th March 2014 received from Aberdeen Asset Management Asia Limited in respect of their holdings in our Company as on 20th March 2014.

Thanking you,

 Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited



Ajay Nadkarni
General Manager – Administration
& Company Secretary

Encl: As Above

FORM C
Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992
(Regulation 13 (3) and (5))

Regulation 13(3) – Details of change in shareholding in respect of persons holding more than 5% shares in a listed company

Name & address of shareholders	Shareholding prior to acquisition/sale	No. & % of shares/voting rights acquired/sold	Receipt of allotment advice/acquisition of shares/sale of shares - specify	Date of intimation to company
Abodeen Asset Management Asia Limited on behalf of funds advised / managed. 21 Church Street #01-01 Capital Square Two Singapore 049480 Tel : 65 6395 2705	GlaxoSmithKline Pharmaceuticals Ltd. 16.4673% (13,948,320 shares)	14.9183% (12,636,245 Shares)	20/03/2014	24/03/2014

Mode of acquisition on (market purchase/public rights/preferential offer etc.)	No. & % of shares/voting rights post-acquisition/s etc	Trading member through whom the trade was executed with SEBI Registration no. of the IM	Exchange on which the trade was executed	Buy quantity	Buy value (Local Currency)	Sell quantity	Sell value (Local Currency)
Open Market Sale	1.549096 (1,312,075 shares)	Credit Suisse Securities (India) Private Limited. INF230970637	NSE			253,272	2,647,7449 per share Total Sell Value 670,599,646.3128
PAN:- AABCPZ26SL AABTA709SC AAMTF2014K AABTC0829N AABIT3942K AALAH5204J AACTA6360K AABCO1823B AABICAB36G AACTM4584F AADCA053SG AABTN1101E AACON071SF AAA TH049SG AAECAD911F AAAAD403SD AABTA9099G AABTT5193Q AAECA9100E AACCT8881L AAJCA7071D AACCT8887F 1004933379 AABTT8980F AACCS2647E AABTG0424F AABTA7094D AAJW0112B AABTN2882L AAJCA7088A AAAJF0103H AACTM7936M							



GlaxoSmithKline

March 26, 2014

**NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA 5TH FLOOR
PLOT No. C/1 G BLOCK
BANDRA-KURLA COMPLEX
BANDRA (EAST)
MUMBAI
400051**

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

Dear Sir,

**SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Pursuant to the Regulation 29(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we enclose herewith an intimation dated 24th March 2014 received from Aberdeen Asset Management Asia Limited in respect of their holdings in our Company as on 20th March 2014.


Thanking you,

 Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited



Ajay Nadkarni
General Manager – Administration
& Company Secretary

Encl: As Above



भारतीय प्रतिभूति और विनियम बोर्ड Securities and Exchange Board of India

Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Ltd.		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Aberdeen Asset Management Asia Limited, on behalf of funds advised / managed.		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange (NSE) Bombay Stock Exchange (BSE)		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	13,948,320	16.4673%	16.4673%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	13,948,320	16.4673%	16.4673%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	-12,636,245	-14.9183%	-14.9183%
b) VRs acquired otherwise than by shares	-	-	-



भारतीय प्रतिभूति और विनियम बोर्ड
Securities and Exchange Board of India

Note:

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / seller / Authorized Signatory

Wannaporn S.

Wannaporn Sirjiwanont

Compliance

For and on behalf of Aberdeen Asset Management Asia Limited

Place : Bangkok

Date : 24/03/2014